Abstract 546: Soluble EphA2 is a potential serum biomarker for lung cancer

Abstract

Abstract EphA2 is a cell surface glycoprotein expresses in various tumor tissues including lung, breast and pancreas carcinoma. As the patients with a highly positive surface expression of EphA2 carcinomas have the poor prognosis, therefore, preclinical and clinical studies using antibody targeting to EphA2 are underlying. Previous study has reported that EphA2 fragment is also released in a soluble form by the proteolytic cleavage from tumor cell surface. In this study, we tried to detect the soluble form of EphA2 (sEphA2) in the serum specimens of lung cancer patients. By using antibodies to EphA2, we developed a new sandwich ELISA system detecting human sEphA2 with high sensitivity and specificity. With this system, we measured the concentration of sEphA2 in the serum of normal healthy donors and lung cancer patients. The concentration of sEphA2 was significantly higher in sera of 15 lung cancer patients than 15 healthy donors (p<0.01). We also examined the other diagnostics biomarkers such as CYFRA and CEA. The levels of sEphA2 in serum of lung cancer patients are correlated with CYFRA and CEA. These data indicate that the diagnosis of the lung cancer enabled by measuring the concentration of sEphA2. However, detail clinicopathological characteristics are necessary for the feasible diagnosis for sEphA2 as a biomarker of lung cancer. Citation Format: Tadanori Kondo, Hiroki Yumoto, Kento Usui, Kazunori Kato. Soluble EphA2 is a potential serum biomarker for lung cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 546. doi:10.1158/1538-7445.AM2015-546